Pulmonx, Corp.

Pulmonx Corporation is a global medical technology company headquartered in Redwood City, California, with operations in Neuchâtel, Switzerland, founded in 1995. The company specializes in minimally invasive bronchoscopic interventions for severe emphysema and chronic obstructive pulmonary disease (COPD). Pulmonx pioneered bronchoscopic lung volume reduction (BLVR) technology and has established itself as a leader in interventional pulmonology solutions for patients unsuitable for or unresponsive to surgical intervention. The company's flagship product portfolio includes the Zephyr® Endobronchial Valve, a clinically validated device that reduces lung hyperinflation by occluding diseased airways, demonstrating significant improvements in lung function (FEV1), exercise capacity, and quality of life across multiple randomized controlled trials. The Chartis® Pulmonary Assessment System provides collateral ventilation assessment to optimize patient selection and treatment planning. The LungTraX Platform delivers cloud-based quantitative CT analysis for personalized treatment planning. Pulmonx's devices are FDA-approved and supported by extensive clinical evidence across four major randomized controlled trials, with over 100 published clinical summaries. The company maintains a global network of treating physicians and assessment centers, with rigorous credentialing criteria including specialized training, hands-on competency, and outcomes monitoring.